TriVascular, Inc.

Begins European Clinical Study of the

Ovation™ Abdominal Stent Graft System

Study Results to Support Application for CE Mark Approval

Santa Rosa, CA, March 22, 2010 – TriVascular, Inc. of Santa Rosa, California,
announced today the first European clinical study implants of its Ovation™ Abdominal
Stent Graft. The innovative, low-profile system is designed to expand the patient
population suitable for endovascular aortic repair (EVAR) by addressing a wider range
of diseased anatomy. Cases were performed in Germany by Thomas Nolte, MD, Chief
of Vascular Surgery at Herz- und Gefäßzentrums Bad Bevensen, and Horst Sievert, MD,
Director of the CardioVascular Center Frankfurt.

"The Ovation Abdominal Stent Graft performed exceptionally well,” said Dr. Nolte,
Principal Investigator for the European study. “The clinical benefits of the reduced
profile and unique sealing technology were evident immediately. I believe this offering
will expand the pool of patients to whom I can offer an endovascular solution.”

The European clinical study will evaluate the safety and performance of the Ovation
Abdominal Stent Graft System. In the United States, the Ovation Abdominal Stent
Graft System is an investigational device and currently not approved for sale.

“I was very pleased with the performance of the Ovation Stent Graft,” said Professor
Sievert. “The system was easy to use and addresses many of the limitations of current
generation devices, especially in cases of difficult anatomy and iliac access.” Professor
Sievert utilized a bilateral percutaneous approach to gain femoral access.

“The start of our European clinical study is a significant milestone for our organization,”
said Mike Chobotov, Ph.D., President and CEO of TriVascular, Inc. “We are fortunate to
partner with thought leading clinicians in Europe. More importantly, we are excited to
provide next generation endovascular solutions to patients suffering from aortic
disease.”

About TriVascular, Inc. - TriVascular's initial product offerings are novel endovascular
grafts designed to significantly advance and expand EVAR. Building upon partnerships
with thought leading clinicians worldwide, TriVascular strives to make products that
address unmet clinical needs and expand the pool of patients who are candidates for
EVAR. Based in Santa Rosa, California, TriVascular offers highly talented, motivated
individuals the opportunity to positively impact global healthcare.

3910 Brickway Blvd., Santa Rosa, CA 95403 Fax 707-543-8600 707-543-8800